Diabetes mellitus

Current Opinion in Neurology

Volumn 10, Issue 5, 1997, Pages 376-380

  Andersen, Henning ^a   Jakobsen, Johannes ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; INSULIN; NEUROTROPHIN; RECEPTOR; SYNTHETIC PEPTIDE; TOLRESTAT;

ANKLE; AUTONOMIC NEUROPATHY; BLOOD FLOW; CLINICAL FEATURE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEUROPATHY; EDEMA; ENDONEURIUM; HUMAN; HYDRATION; INSULIN DEPENDENT DIABETES MELLITUS; LEG AMPUTATION; LOWER LEG; MAJOR CLINICAL STUDY; NERVE; NON INSULIN DEPENDENT DIABETES MELLITUS; RECEPTOR AFFINITY; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030873926     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199710000-00004     Document Type: Review

References (21)

1. Tesfaye S, Stevens LK, Stephenson JM, Fuller JH, Plater M, Ionescu-Tirgoviste C, Nuber A, Pozza G, Ward JD, and the EURODIAB IDDM Study Group: Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetologia 1996, 39:1377-1384. A large scale hospital based epidemiological study identifying risk factors for neuropathy.
2. Stephenson JM, Kempler P, Cavallo Perin P, Fuller JH, and the EURODIABIDDM Complications Study. Is autonomic neuropathy a risk factor for severe hypoglycemia? The EURODIAB IDDM Complications Study. Diabetologia 1996, 39:1372-1376.
3. Savage S, Estacio RO, Jeffers B, Schrier RW: Urinary albumin excretion as a predictor of diabetic retinopathy, neuropathy, and cardiovascular disease in NIDDM. Diabetes Care 1996, 19:1243-1248.
4. Lehto S, Rönnemaa T, Pyörälä K, Laakso M: Risk factors predicting lower extremity amputations in patients with NIDDM. Diabetes Care 1996, 19:607-612. A follow-up study of NIDDM patients identifying risk factors for lower limb amputation.
5. Andersen H, Poulsen PL, Mogensen CE, Jakobsen J: Isokinetic muscle strength in long-term IDDM patients In relation to diabetic complications. Diabetes 1996, 45:440-445.
6. Andersen H, Mogensen PH: Disordered mobility of large joints in association with neuropathy in patients with long-standing insulin-dependent diabetes mellitus. Diabet Med 1997, 14:221-228.
7. Samsom M, Jebbink RJA, Akkermans LMA, vanBerge-Henegouwen GP, Smout AJPM: Abnormalities of antroduodenal motility in type 1 diabetes. Diabetes Care 1996, 19:21-27.
8. Okano HY, Inui A, Ueno N, Morimoto S, Ohmoto A, Miyamoto M, Aoyama N, Nakajima Y, Baba S, Kasuga M: EM523L, a nonpeptide motilin agonist, stimulates gastric emptying and pancreatic polypeptide secretion. Peptides 1996, 17:895-900.
9. Camilleri M, Balm RK, Zinsmeister AR: Symptomatic improvement with one-year cisapride treatment in neuropathic chronic intestinal dysmotility. Ailment Pharmacol Ther 1996, 10:403-409.
10. Persico M, Suozzo R, De Setas M, Montella F, Torella R, Gentile S: Non-ulcer dyspepsia and Helicobacter pylori in type 2 diabetic patients: association with autonomic neuropathy. Diabetes Res Clin Prac 1996, 31:87-92.
11. Cameron NE, Cotter MA: Interaction between oxidative stress and γ-linolenic acid in impaired neurovascular function of diabetic rats. Am J Physiol 1996, 271:E471-E476.
12. Eaton RP, Qualls C, Bicknell J, Sibbitt Jr WL, King MK, Griffey RH: Structure-function relationships within peripheral nerves in diabetic neuropathy: the hydration hypothesis. Diabetologia 1996, 39:439-446. The study applies a new technique for evaluation of peripheral nerve biochemistry in vivo and provides new and interesting findings.
13. Tesfaye S, Malik R, Harris N, Jakubowski JJ, Mody C, Rennie IG, Ward JD: Arterio-venous shunting and proliferating new vessels in acute painful neuropathy of rapid glycaemic control (insulin neuritis). Diabetologia 1996, 39:329-335.
14. Plater ME, Ford I, Dent MT, Preston FE, Ward JD: Elevated von Willebrand factor antigen predicts deterioration in diabetic peripheral nerve function. Diabetologia 1996, 39:336-343.
15. Veves A, Donaghue VM, Sarnow MR, Giurini JM, Campbell DR, LoGerfo FW: The impact of reversal of hypoxia by revascularization on the peripheral nerve function of diabetic patients. Diabetologia 1996, 39:344-348.
16. NGFR in human diabetic neuropathy. J Neurol Sci 1996, 135:55-62. An innovative study suggesting that axonal nerve fiber degeneration can be modified pharmacologically.
17. Dyck PJ, Peroutka S, Rask C, Burton E, Baker MK, Lehman KA, Gillen DA, Hokanson JL, O'Brien PC: Intradermal recombinant human nerve growth factor induces pressure allodynia and lowered heat-pain threshold in humans. Neurology 1997, 48:501-505.
18. The Diabetes Control and Complications Trial Research Group: The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995, 122:561-568
19. Nicolucci A, Carinci F, Graepel JG, Hohman TC, Ferris F, Lachin JM: The efficacy of tolrestat in the treatment of diabetic peripheral neuropathy. A meta-analysis of individual patient data. Diabetes Care 1996, 19:1091-1096.
20. Orskov L, Worm M, Schmitz O, Mengel A, Sidenius P: Nerve conduction velocity in man: influence of glucose, somatostatin and electrolytes. Diabetologia 1994, 37:1216-1220.
21. Valk GD, Kappelle AC, Tjon-A-Tsien AML, Bravenboer B, Bakker K, Michels RPJ, Groenhout CM, Bertelsmann FW: Treatment of diabetic polyneuropathy with the neurotrophic peptide ORG 2766. J Neurol 1996, 243:257-263.